Drug-induced liver injury (DILI) is a potentially lethal condition that heavily impacts the pharmaceutical industry, causing drug withdrawals and approximately 13% of clinical trial failures. The prevalence of DILI in clinical settings exposes the limitations of preclinical toxicology models, which fail to capture the complexity of human liver physiology and its response to drug exposure.
Recent evidence suggests that adopting the Emulate Liver-Chip into preclinical workflows may reduce DILI-related clinical trial failures. Here, we present a quantitative framework for integrating Liver-Chip data into the pharmaceutical decision-making process. This new Liver-Chip DILI score enables researchers to categorize tested compounds into standard DILI risk categories utilizing human Liver-Chip and animal in vivo data.
During this webinar, topics that were covered included:
- Characterization results of the Emulate Liver-Chip within the context of use of DILI prediction
- Where in the preclinical workflow the Liver-Chip can be deployed
- How the Liver-Chip’s quantitative readouts can be used to map prospective therapeutics into standard DILI risk categories
- Methodology for combining Liver-Chip data with animal in vivo data, allowing for a more holistic assessment of DILI risk ahead of clinical trial testing
The presentation was followed by an informative Q&A session.